CAESAREA, Israel, Oct. 3, 2018 /PRNewswire/ — V-Wave Ltd. announced today that it has enrolled the first patients in its global, 500 patient pivotal study of its proprietary, minimally invasive implanted interatrial shunt device for treating patients with NHYA Class III and ambulatory Class IV symptomatic heart failure (HF). This randomized, controlled, double-blinded […]
Author: Ken Dropiewski
Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions
NEW YORK and MELBOURNE, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the 159-patient randomized placebo-controlled Phase 2b trial evaluating its allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM in the treatment of end-stage heart failure patients implanted with a left ventricular assist device (LVAD) has […]
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
LAVAL, Québec, Oct. 01, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced its election to issue common shares to the holders of its outstanding convertible debentures in satisfaction of interest payable. In accordance with the terms of its outstanding convertible […]
Zenosense, Inc.: MIDS Medical Expands Technical Team
VALENCIA, SPAIN, Oct. 02, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Zenosense, Inc. (OTCQB: ZENO, “Zenosense”, the “Company”), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce […]
Hancock Jaffe Appoints Three New Independent Directors
IRVINE, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has appointed accomplished medical device professionals Dr. Francis Duhay and Dr. Sanjay Shrivastava, and recognized fund manager and equity […]
Biotricity Provides Fiscal 2018 Second Quarter Updates for Shareholders
REDWOOD CITY, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today provided operational updates for its fiscal 2018 second quarter which ended September 30, 2018. Bioflux 1.0 sales growth and market expansion achieved a record high during the fiscal 2018 second quarter; the […]
Merit Medical Signs Agreement to Acquire Cianna Medical, Inc.
SOUTH JORDAN, Utah, Oct. 01, 2018 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it has signed a definitive merger agreement […]
PureFlow is a breakthrough technology in non-invasive cardiology and sports recovery; is now FDA 510K and MDD 93/42/ EEC cleared
NEW YORK, Oct. 2, 2018 /PRNewswire/ — Xtreem Pulse LLC is pleased to announce that PureFlow received 510Kclearance from the FDA for chronic stable angina that is refractory to optimal anti-anginal medical therapy and without option for revascularization. Intended for use in healthy patients to provide improvement in vasodilation, increased VO2, and increased […]
Cardax Launches Human Clinical Trial Targeting Cardiovascular Inflammatory Health
HONOLULU, Oct. 2, 2018 /PRNewswire/ — Cardax, Inc. (OTCQB: CDXI) has launched its Cardiovascular Health Astaxanthin Supplement Evaluation (CHASE) clinical trial targeting cardiovascular inflammatory health. The first subject was dosed on September 19, 2018. The randomized, double-blind, placebo-controlled CHASE clinical trial will evaluate the effect of low-dose and high-dose ZanthoSyn®, Cardax’s premium astaxanthin supplement, on cardiovascular health, as measured […]
CathVision Receives ISO 13485:2016 Certification
COPENHAGEN, Denmark, October 2, 2018 /PRNewswire/ — CathVision ApS, an early stage medical device company developing an advanced cardiac electrophysiology recording system, CUBE, announced today that the company received ISO 13485:2016 certification for Medical Device and Quality Management Systems from Lloyd’s Register. This ISO certification indicates that the company’s quality management system meets the […]
Recent
Nyra Medical Receives Prestigious Jon DeHaan Foundation Award for Innovation in Cardiology at EuroPCR 2026
AHN’s Allegheny General Hospital Unveils New, State-of-the-Art Cardiac Cath and Electrophysiology Labs, following Completion of $19 Million Renovation Project
egnite Expands Medical Advisory Board with Three Nationally Recognized Cardiovascular Specialists
Popular
- No commented posts yet